| Subject: | FDA Alerts Healthcare Professionals To The Risks Of Using Simvastatin With Amiodarone |
| Category: | Food and Drug Administration (FDA)
|
| Published: | Mon, 11 Aug 2008 - 09:00 am |
| Audience: Cardiologic healthcare professionals, pharmacists, other healthcare professionalsThe FDA is notifying healthcare professionals of the risk of rhabdomyolysis which can lead to kidney failure or death, when simvastatin is used with amiodarone. This risk is dose-related and increases when a dose of simvastatin greater than 20 mg per day is given with amiodarone. Although a revision of the simvastatin labeling in 2002 described an increased risk of rhabdomyolysis when amiodarone is taken... The full article is available to StayAlert subscribers. Click here for a free trial subscription. |
|
RESOURCES:
External Links:
|
|
StayAlert! notifies healthcare customers of all federal and regulatory body legislation changes impacting the healthcare industry, including TJC (JCAHO), CDC, CMS, DHHS, FDA, OSHA, OIG and many others. StayAlert! complements this with regulatory implementation action plans. StayAlert! serves as a virtual healthcare department, augmenting traditional employee staffed departments and freeing employees to perform other vital functions. StayAlert! is the only comprehensive clinical and regulatory service providing organizations in the healthcare arena with practical applications to meet complex mandated federal requirements. |
|
